Weiss Multi-Strategy Advisers’s Blueprint Medicines BPMC Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-5,023	Closed	-$392K	–	462
2018 Q3	$392K	Buy	5,023 +23	+0.5%	+$1.6K	0.01%	464
2018 Q2	$317K	Buy	+5,000	New	+$398K	0.01%	508
2017 Q3	–	Sell	-10,000	Closed	-$507K	–	497
2017 Q2	$507K	Hold	10,000	–	–	0.02%	438
2017 Q1	$400K	Buy	+10,000	New	+$358K	0.02%	479

Other funds holding BPMC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Weiss Multi-Strategy Advisers's BPMC Position: Q4 2018 in Review

Weiss Multi-Strategy Advisers sold out of Blueprint Medicines (BPMC) in Q4 2018, closing a stake of 5,023 shares — an estimated $392K sold.

Weiss Multi-Strategy Advisers first reported a position in BPMC in Q1 2017 and held it in 4 quarters. The position peaked at $507K in Q2 2017. 162 funds tracked by Wall St. Rank hold BPMC as of Q4 2018.

Weiss Multi-Strategy Advisers reported no remaining Blueprint Medicines position as of Q4 2018 after selling out during the quarter.
Weiss Multi-Strategy Advisers sold 5,023 Blueprint Medicines shares in Q4 2018, an estimated $392K.
Weiss Multi-Strategy Advisers first reported a position in Blueprint Medicines in Q1 2017 and held it in 4 quarters.
Weiss Multi-Strategy Advisers's Blueprint Medicines position peaked at $507K in Q2 2017.
162 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2018.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q4 2018, filed 14 Feb 2019.